Accessibility Menu
Yubo International Biotech logo

Yubo International Biotech(OTC) YBGJ

Market Cap$2.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 Year-99%
1 Year-89%
1 Month+100%
$0.01
+0%
+0.00Today
Yubo International Biotech last closing stock price
MetricPriceDate
Last closeUSD 0.012026-07-22
Yubo International Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.04%USD 0.012026-07-15
1 month+100%USD 0.012026-06-16
3 month+40%USD 0.012026-04-15
Year to date+12.9%USD 0.012025-12-31
1 year-89.22%USD 0.132025-07-22
3 year-95.88%USD 0.342023-07-18
5 year-98.73%USD 1.102021-07-19
Since inception-99.56%USD 3.202021-01-15

Yubo International Biotech Financials at a Glance

Market Cap

$2.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$134.39K

Net Income (TTM)

-$916.23K

EPS (TTM)

-$0.01

P/E Ratio

-2.03

Dividend

$0.00

Beta (Volatility)

-0.64 (Low)

Price

$0.01

Volume

2,000

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.01 - $0.05

Estimated Earnings Date

Mar 31, 2026

YBGJ News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Yubo International Biotech

Yubo develops healthcare and personal care products using stem cell technology. Its offerings help people manage skin, hair, and respiratory health. The company also provides cell testing and health consulting services in China.

Products and Services

  • Respiratory Health Products: Nebulizers and medical fluids are among the light application products that accounted for 100% of 2025 revenue.
  • Skincare Solutions: Masks and essences for skin renewal and care.
  • Hair Care Products: Treatments aimed at strengthening hair and scalp health.
  • Healthy Beverages: Drinks with cell-based ingredients for general wellness.
  • Personal Care Items: Products for male and female hygiene and comfort.
  • Stem Cell Services: Cell testing and health management consulting under the VIVCELL brand.

Growth and Expansion

  • Launched respiratory atomization product in April 2020 and wellness drink in February 2021.
  • Started construction of a stem cell bank in Chengdu, China, with phased rollout planned through 2035.
  • Expanded product promotion to new regional markets in China since 2021.
  • Adopted a franchise model for biological experience centers to display and sell products.

What Makes Yubo Stand Out

Yubo integrates stem cell research, product development, and retail under one brand. It holds a Chinese patent for a menstrual blood collection kit, supporting its focus on endometrial stem cell technology. The company’s business model covers collection, storage, and consumer-facing sales channels.

Five Things You Need to Know

  • Revenue was $12,353 in 2025, up 256% from 2024.
  • All 2025 revenue came from one customer and one product category.
  • Net loss was $1.19 million in 2025, down 40% from 2024.
  • Cash at year-end 2025 was $8,062, with negative working capital of $2.12 million.
  • Ongoing operations depend on shareholder loans and related party financing.

Bottom Line

Yubo is an early-stage healthcare company with a focus on stem cell technology. It faces financial and operational challenges but continues to develop new products and expand its market presence in China.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

14

CEO

Wang Yang, MBA

Website

www.yubogroup.com

Headquarters

Beijing, BE 100026, CN

YBGJ Financials

Key Financial Metrics (TTM)

Gross Margin

15.83%

Operating Margin

-751.29%

Net Income Margin

-681.76%

Return on Equity

36.96%

Return on Capital

N/A

Return on Assets

-129.07%

Earnings Yield

-49.26%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

170.42M

Volume

2.00K

Avg. Volume

3.23K

Financials (TTM)

Gross Profit

$21.27K

Operating Income

-$1.01M

EBITDA

-$1.01M

Operating Cash Flow

-$249.39K

Capital Expenditure

$6.18K

Free Cash Flow

-$243.22K

Cash & ST Invst.

$10.38K

Total Debt

$39.22K

Yubo International Biotech Performance Analysis

Yubo International Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 104,283-91.6%
20232023-12-31USD 604,676479.8%
20242024-12-31USD 3,470-99.4%
20252025-12-31USD 12,353256.0%
Yubo International Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31-100.0%
Yubo International Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.01-22.1%
20232023-12-31USD -0.01-2.0%
20242024-12-31USD -0.0148.0%
20252025-12-31USD -0.01-48.0%
Yubo International Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3047.2%
Q32025-09-30N/A
Q42025-12-3121.1%
Q12026-03-31-6.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$31.52K

+29.4%

Gross Margin

0.00%

N/A

Market Cap

$2.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$170.42K

N/A

Employees

14

N/A

Net Income

-$272.61K

+37.4%

EBITDA

-$269.28K

+36.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$10.38K

+6.2%

Total Debt

$39.22K

-83.1%

Accounts Receivable

$134.22K

-68.5%

Inventory

$24.41K

-34.4%

Long Term Debt

$0.00

-100.0%

Short Term Debt

$39.22K

-80.4%

Return on Assets

-1.29%

N/A

Return on Invested Capital

43.72%

N/A

Free Cash Flow

-$207.16K

+48.0%

Operating Cash Flow

-$207.16K

+47.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IVROInVitro International
$0.07+8.09%
SHMNSOHM, Inc.
$0.00+0.00%
EVIOEVIO, Inc.
$0.00+0.00%
HEMPHemp, Inc
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.13+0.11%
NVDANvidia
$195.04+0.03%
MSFTMicrosoft
$451.10+0.16%
NOKNokia
$9.09+0.08%

Questions About YBGJ

What is the current price of Yubo International Biotech?

Yubo International Biotech is trading at $0.01 per share.

What is the 52-week range for Yubo International Biotech?

Over the past 52 weeks, Yubo International Biotech has traded between $0.01 and $0.05.

How much debt does Yubo International Biotech have?

As of the most recent reporting period, Yubo International Biotech reported total debt of $39.22K.

How much cash does Yubo International Biotech have on hand?

Yubo International Biotech reported $10.38K in cash and cash equivalents in its most recent financial results.

What is Yubo International Biotech’s dividend yield?

Yubo International Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services